Charity's plea on breast cancer drug

The first drug of its type could give secondary breast cancer patients an extra six months with their families.

That's the claim from Breakthrough Breast Cancer as it urges authorities to licence Kadcyla - or TDM-1 - here. It wants the Scottish Medicines Consortium to approve its use here as soon as possible. The charity's Scottish director, James Joppling, tells us how the drug works:

More from Local News